Abstract. Balanites aegyptiaca is a widely distributed African plant of medicinal interest containing a number of cytotoxic and cytostatic compounds. The studies reported here have attempted to further characterize the anti-cancer activity of a mixture of steroidal saponins: balanitin-6 (28%) and balanitin-7 (72%) isolated from Balanites aegyptiaca kernels. The balanitin-6 and -7 mixture (henceforth referred to as bal6/7) has demonstrated appreciable anti-cancer effects in human cancer cell lines in vitro. Bal6/7 displayed higher anti-proliferative activity than etoposide and oxaliplatin, although the mixture was appreciably less active than SN38 and markedly less active than taxol. Bal6/7 demonstrated highest activity against A549 non-small cell lung cancer (NSCLC) (IC 50 , 0.3 μM) and U373 glioblastoma (IC 50 , 0.5 μM) cell lines. The current study has further indicated that bal6/7 is more a cytotoxic compound than a cytostatic one. However, Bal6/7 does not appear to mediate its anti-proliferative effects by inducing apoptotic cell death. Computer-assisted cellular imaging has revealed that bal6/7 does not induce detergent-like effects in A549 NSCLC and U373 glioblastoma unlike certain saponins. Furthermore there is indication that its in vitro anti-cancer activities result at least partly from depletion of [ATP] i , leading in turn to major disorganization of actin cytoskeleton, ultimately resulting in the impairment of cancer cell proliferation and migration. In contrast to a number of natural products acting as anti-cancer agents, bal6/7 does not induce an increase in intra-cellular reactive oxygen species. In vivo, bal6/7 increased the survival time of mice bearing murine L1210 leukemia grafts to the same extent reported for vincristine. These preliminary in vivo data suggest that it may be possible to generate novel hemisynthetic derivatives of balanitin-6 and -7 with potentially improved in vitro and in vivo anti-cancer activity and reduced in vivo toxicity, thus markedly improving the therapeutic ratio.
Introduction
Balanites aegyptiaca Del. (Balanitaceae) is a widely distributed African plant of medicinal interest (1, 2) . It is a small spinescent evergreen savanna tree with a dark brown stem which usually attains a height of 4.5-6 m (3). In Egyptian folk medicine, the fruits are used as an oral hypoglycemic (4) and an anti-diabetic (5) . An aqueous extract of the fruit mesocarp is used in Sudanese folk medicine in the treatment of jaundice (5) and as an anthelmintic (3) . Indeed the plant is used as a purge to remove intestinal parasites with the root, branches, bark, fruit and kernel extracts shown to be lethal to the miracidia and cercariae of Shistosoma mansoni and to Fasciola gigantica (3, 6) . Additionally extracts of the tree display abortive and antiseptic properties (2) .
The bark of Balanites aegyptiaca contains a number of alkaloids such as N-trans-feruloyltyramine and N-cisferuloyltyramine (5) and common phenolic compounds such as vanillic acid, syringic acid and 3-hydroxy-1-(4-hydroxy-3-methoxyphenyl)-1-propanone (5) . The roots and bark also contain numerous steroidal saponins and yamogenin or diosgenin glycosides (2) . The fruit mesocarp contains a large variety of chemicals amongst which are the pregnane glycosides (1), coumarins (2) , flavonoids (2), 6-methyldiosgenin (2) and furostanol saponins (1, 4) . The saponins are a structurally and biologically diverse class of glycosides of both steroids and triterpenes that are widely distributed in terrestrial plants and in some marine organisms (7) . Diosgenyl saponins are the most abundant (7) and present typical oligosaccharide chains in which the first sugar, ß-D-glucopyranoside is attached to diosgenin via the 3-OH position, and the ß-Dglucopyranoside is itself substituted via its 2-OH and 4-OH positions respectively by α-L-rhamnopyranose and other sugars or sugar chains. Dioscin, polyphyllin D and balanitins ( Fig. 1 ) belong to this class (7) .
Methanol and butanol extracts of Balanites aegyptiaca initially afforded two novel saponins with anti-inflammatory properties, balanitin-1 and -2 (2). Bioactivity-guided separation of a CH 2 Cl 2 /MeOH extract of Balanites aegyptica identified four further novel balanitins, -4, -5, -6 and -7, which were found to have cytostatic activity ( Fig. 1) (8) .
The aim of the present study was to further characterize the anti-tumor activity of balanitin-6 and -7 and to decipher their mechanism(s) of action. For this purpose, a mixture containing balanitin-6 and -7 (bal6/7: ~28% and 72%, respectively) extracted from Balanites aegyptiaca kernels was evaluated in vitro for anti-cancer activity against six different human cancer cell lines using the MTT colorimetric assay (9) and in vivo in the murine L1210 leukemia model (16) . Additionally, computer-assisted quantitative videomicroscopy (10-13) has been used to investigate how bal6/7 reduces the overall growth rate of A549 non-small cell lung cancer [NSCLC; (14) ] and U373 glioblastoma (15) cell lines, and whether bal6/7 destroys cancer cells simply by detergent-related effects. Additionally the impact of bal6/7 on intra-cellular concentrations of ATP [ATP] i and reactive oxygen species [ROS] i and the organization of the actin cytoskeleton have been investigated.
Materials and methods
Balanitin isolation. Balanitin-6 and -7 have been isolated from Balanites aegyptiaca using a procedure similar to one previously described (8) . Powdered kernels (504 g) from Balanites aegyptiaca were extracted with distilled water (4 times with 1.5 l) over 3 h at ambient temperature and the combined extracts filtered and reduced in volume to obtain a concentrate (500 ml). The concentrate was then extracted with an equal volume of n-butanol which on evaporation yielded 39 g of solid matter. This solid was dissolved in methanol (125 ml) and then chromatographed on an LH-20 column (2.5 kg; 105x10 cm) using methanol (25 l) as the eluent. Eluted fractions were monitored by TLC using CH 2 Cl 2 / MeOH (v/v: 8/2) as the solvent. All fractions containing a component with an Rf of 0.27 were combined and evaporated Figure 1 . Chemical structures of balanitin-6 and -7. The arrows point to the differences between balanitin-6 and balanitin-7: the lack of a xylose in balanitin-6 when compared to balanitin-7 and an axial C26 methyl position for balanitin-6 (yamogenin) and an equatorial for balanitin-7 (diosgenin).
to dryness to give a solid of 24 g. This solid was redissolved in 75 ml of CH 2 Cl 2 /MeOH (v/v: 2/3) and re-chromatographed on a Sephadex LH-20 column with CH 2 Cl 2 /MeOH (v/v: 2/3) used as the eluent. Eluted fractions were again analyzed by TLC as indicated above and those containing the component of Rf of 0.27 were combined and evaporated to dryness to give 19 g of solid. This latter product was subject to flash chromatography on a silica gel column and eluted with CHCl 3 / MeOH (v/v: 9/1) to give two fractions (0.186 g and 1.9 g after evaporation). The first fraction (containing 0.186 g of the product with a TLC Rf of 0.27) was subject to further flash chromatography on a C18 reverse phase column (50x3 cm) and eluted with MeOH/H 2 O (v/v: 9/1) to afford a fraction containing 37 mg of a mixture of balanitin-6 and -7 (TLC Rf of 0.27 using the conditions described above).
The structures of balanitin-6 and -7 were confirmed using ESI mass spectrometry on a Micromass ZQ and 1 H and 13 C NMR spectroscopy using a Varian unity 300 instrument and by comparison with literature data (8; Fig. 2 ). HPLC analyses were performed on an Alliance HPLC system. Chromatographic separation of balanitin-6 and -7 and confirmation of structures. A, LC-MS total ion current (TIC) chromatogram of the final isolated mixture of balanitin-6 (Rt, 10.48 min) and balanitin-7 (Rt, 9.79 min). The LC-MS TIC chromatograph of the sample was obtained by monitoring for a characteristic fragment ion at m/z 271 common to both balanitin-6 and -7. The units of the x-axis are retention time expressed in minutes, while the units of the y-axis are the relative abundance of each compound expressed as a percentage. The relative abundance should be considered an estimate given that TIC determinations have to make the assumption of an identical level of ionization/fragmentation for balanitin-6 and -7, which may not be the case. B, 13 C-NMR: characteristic chemical shifts (δ ppm) for balanitin-6 and -7 from the literature in pyridine-d5 (8) and the plant isolated sample (mixture of balanitin-6 and -7). C, ESI-MS fragment ion data for balanitin-7. The assignments of ions are given in brackets and the relative intensities expressed as percentages. The mass units which are lost correspond to the following fragments: 132, xylose; 146, rhamnose; 278, xylose + rhamnose; 294, xylose + glucose; 440, xylose + rhamnose + glucose; 602, xylose + rhamnose + two glucose moieties; and 746, fragmentation of the steroidal moiety. D, ESI-MS fragment ion data for balanitin-6. The assignments of ions are given in brackets and the relative intensities expressed as percentages. The mass units which are lost correspond to the following fragments: 146, rhamnose; 162, glucose; 308, rhamnose + glucose; 470, rhamnose + two glucose moieties; and 614, fragmentation of the steroidal moiety.
Compounds. Drugs were obtained as follows: taxol (Paclitaxel; S.A. Bristol-Myers Squibb, Brussels, Belgium), SN38 (7-ethyl-10-hydroxycamptothecin; Aventis, Brussels, Belgium), oxaliplatin (Inter-Chemical Ltd, ShenZhen, P.R. China), etoposide (VP16, Bristol-Myers Squibb, Brussels, Belgium) and doxorubicin (Adriamycin, Pfizer Pharmacia, Puurs, Belgium). Glycine, L-fructose and D-glucose were purchased from Sigma (Bornem, Belgium).
Culture media and cancer cell lines. All human cancer cell lines used in this study were obtained from the American Type Culture Collection (Manassas, USA) and included A549 NSCLC (ATCC code CCL-185), U373 glioblastoma (ATCC code HTB-17), PC-3 refractory prostate cancer (ATCC code CRL-1435), Bx-PC3 pancreatic cancer (ATCC code CRL-1687), LoVo colon cancer (ATCC code CCL-229) and MCF-7 breast cancer (ATCC code HTB-22) cell lines. The cells were maintained as described previously (9, 13) . All culture media were supplemented with a mixture of 0.6 mg/ml glutamine (GibcoBRL, Invitrogen, Merelbeke, Belgium), 200 IU/ml penicillin (GibcoBRL), 200 IU/ml streptomycin (GibcoBRL) and 0.1 mg/ml gentamycin (GibcoBRL). The FCS (GibcoBRL) was heat-inactivated for 1 h at 56˚C. The cells were incubated at 37˚C in sealed (air-tight) Falcon plastic dishes (Nunc, Invitrogen SA, Merelbeke, Belgium) in a 5% CO 2 atmosphere.
MTT colorimetric assay for global cell growth determination.
Overall cell growth was assessed by means of the colorimetric MTT [3-(4,5-dimethylthiazol-2yl)-diphenyltetrazolium bromide; Sigma] assay, as detailed previously (10, (13) (14) (15) . The 6 cell lines were incubated for 24 h in 96-microwell plates (at a level of 10,000-40,000 cells/ml of culture medium depending on the cell type) to ensure adequate plating prior to cell growth determination. This assay of cell population growth is based on the capability of living cells to reduce the yellow product MTT to its blue metabolite formazan by reduction in mitochondria. The number of living cells after 72-h incubation in the presence or absence (control) of test compounds or reference drugs is directly proportional to the intensity of the blue, which is quantitatively measured by spectrophotometry using a DIAS microplate reader (Dynatech Laboratories) at a wavelength of 570 nm (with a reference of 630 nm). Each experiment was carried out in sextuplicate. Nine concentrations ranging from 10 -5 to 10 -9 M (with semilog increases in concentration) were assayed for each tested compound under study.
Cellular imaging for visualizing bal6/7-induced effects on living cancer cells.
Human A549 NSCLC and U373 glioblastoma cell migration and proliferation with and without compound treatment were visualized in vitro by quantitative videomicroscopy, as previously described (11) (12) (13) 17) .
Immunofluorescence analyses of actin cytoskeleton. For immunofluorescence analyses, cells were rinsed twice in cold PBS, fixed in 4% formol for 20 min at 4˚C and then rinsed twice more in cold PBS. Phallacidin conjugated with Alexa Fluor ® 488 fluorochrome (Molecular Probes Inc., Eugene, USA) was used to label the fibrillar actin, and Alexa Fluor ® 594-conjugated DNAseI (Molecular Probes Inc) to stain the globular actin. Cells were cultured for up to 6 h in the presence or absence of bal6/7 at the IC 75 concentration (470 nM for A549 and 830 nM for U373 cells) on glass coverslips prior to staining. Fluorescence was visualized by a computer-assisted Olympus AX70 microscope (Omnilabo, Antwerp, Belgium) equipped with a Megaview2 digital camera and analySIS ® software (Soft Imaging System, Munster, Germany), as detailed elsewhere (13) .
Flow cytometry analyses for cell cycle and cell death determination
Cell cycle. The cell cycle kinetics of the A549 cells either treated with bal6/7 or left untreated were determined by flow 50 and IC 75 values correspond respectively to concentrations that reduced by 50% and 75% the global growth of the cancer cell lines after three days of culturing in the presence of the compounds and are reported as the means calculated from six separate determinations. For the sake of clarity, rounded values are given (i.e. A549 NSCLC IC 75 : 0.5 μM instead of 470 nM) and the SEM values are not reported. Additionally, it should be noted that the highest SEM value calculated was <5% of its mean value.
cytometry analysis of propidium iodide (PI) nuclear staining using a previously detailed methodology (18) .
Apoptosis. Flow cytometry analysis of apoptotic versus nonapoptotic-related cell death was performed according to the experimental protocol detailed by Darzynkiewicz et al (19) . Briefly, after various treatments with bal6/7 the cells were incubated in the dark in an annexin V-FITC (V) and PI solution for 15 min at 4˚C (APO-AF kit; Sigma). Data from approximately 10,000 cells were recorded for each sample. An 'XL System II' Beckman Coulter (Miami, FL) was used to give a precise definition of both the percentage of cells in the apoptotic and/or non-apoptotic compartments and the percentage of normal cells, i.e. those apparently left unaffected by the bal6/7 treatment. The so-called normal cells were negative for both the annexin V and the PI staining, while the early apoptotic cells were positive for annexin V but negative for PI. The late-apoptotic cells (whose cell membranes are perforated) were positive for both PI and annexin V. Each experiment was carried out in triplicate. Human MCF-7 breast cancer cells untreated or treated with doxorubicin (5 μM for 36 h) were used as the positive control for the experiment.
Cellular ATP measurements.
[ATP] i was measured using a bioluminescence assay according to the manufacturer's instructions (Invitrogen, Merelbeke, Belgium) in A549 NSCLC and in U373 glioblastoma cells cultured in the presence or absence of bal6/7 at IC 75 concentrations (470 and 830 nM, respectively) for 24-72 h (17) . Three replicate determinations per time point were performed for each cell line.
Flow cytometry analyses for the determination of ROS production. Reactive oxygen species (ROS) production was determined using 2',7'-dichlorodihydrofluorescein diacetate (DCFH-DA; Fluka-Sigma, Bornem, Belgium). After A549 and U373 cells were treated with bal6/7 IC 75 concentrations (470 and 830 nM, respectively) for 24-72 h, they were loaded for 1 h with DCFH-DA (20 μM) in RPMI-1640 medium without phenol-red. The acetoxymethyl group on DCFH-DA is cleaved by non-specific esterases within the cell, resulting in a non-fluorescent charged molecule that does not cross the cell membrane. Intra-cellular ROS irreversibly oxidizes the DCFH-DA to dichlorofluorescein (DCF), which is a fluorescent product. Ten thousand individual data points were collected for each sample using a Becton Dickinson FACScan flow cytometer (excitation 488 nm/emission 535 nm). Each experimental condition was evaluated in triplicate. Human MCF-7 breast cancer cells untreated or treated with H 2 O 2 (4 mM for 1h) were used as the positive control for the experiment.
In vivo L1210 leukemia-related experiments. The anti-tumor activity of bal6/7 was evaluated in vivo in a previously described primary screening model of L1210 syngeneic murine leukemia (16) . L1210 leukemia cells (10 6 ) were injected into 5-to 6-week old female B6D2F1 (C57BlxDBA/ 2f/F1) mice (Charles River, L'Arbresle, France) on day 0. Bal6/7 was then administered i.p. at dose levels of 1.25, 2.5 and 5 mg/kg from days 1 to 4 and from days 8 to 11 (regimen: 4 injections per week for 2 weeks) and the median survival time of drug-treated (T) groups was compared to that of the control (C) group which received no drug treatment to obtain the %T/C index. Each experimental group was composed of 9 mice. Animals were housed in plastic cages in light-(12 h night/day cycle), temperature-(22±2˚C) and humidity-(55±5%) controlled rooms. Rodent diet (AO4, UAR, Villemoisson, France) and water were provided ad libitum. All in vivo experiments were performed on the basis of authorization received from the Belgian Animal Ethics Committee of the Federal Department of Health, Nutritional Safety and the Environment (no. LA1230509).
Statistical analyses. Statistical analyses were performed using Statistica software (Statsoft, Tulsa, USA). Statistical comparison of control and treated groups was initially undertaken with the Kruskal-Wallis test (a non-parametric one-way analysis of variance). The levels of statistical significance associated with the %T/C survival indices were determined using Gehan's generalized Wilcoxon test.
Results

Bal6/7 IC 50 and IC 75 values for the inhibition of the proliferation of six human cancer cell lines.
The IC 50 and IC 75 values determined for bal6/7 and four marketed cytotoxic drugs used to combat various types of cancers, oxaliplatin (OXA), etoposide (VP16), SN38 (the active metabolite of irinotecan) and taxol, are reported in Table I . The data reveal that bal6/7 displays higher anti-proliferative activity than etoposide and oxaliplatin, although the mixture was appreciably less active than SN38 and markedly less active than taxol. Bal6/7 demonstrated the highest activity against A549 NSCLC (IC 50 , 0.3 μM) and U373 glioblastoma (IC 50 , 0.5 μM) cell lines. Fig. 3A illustrates the typical morphology of untreated human A549 NSCLC cells at the beginning (t = 0 min) of image recording using computer-assisted phasecontrast microscopy, while Fig. 3B illustrates the situation 72 h later. Fig. 3C and D shows the corresponding still images at 0 min and 72 h of A549 NSCLC cells treated with bal6/7 at its IC 75 of 470 nM (Table I ). Fig. 3D shows that those A549 NSCLC cells that escaped the anti-proliferative/cytotoxic effects of bal6/7 displayed increased size and were more flattened in appearance than control A549 cells (Fig. 3A) . These cells also moved more slowly indicative of a bal6/7 effect on cell migration. Such modifications of A549 cell shape on bal6/7 treatment are compatible with modifications to the actin cytoskeleton organization, a feature that has also been investigated in the present study. The video (data not shown) clearly indicates that bal6/7 did not induce detergentlike effects, as has been observed for some saponins, since no cell 'explosions' were observed. Fig. 3E -H illustrates the same effects of bal6/7 in human U373 glioblastoma cells as seen in A549 NSCLC cells. Fig. 4A shows that bal6/7 does not markedly modify A549 NSCLC or U373 glioblastoma cell cycle kinetic parameters, i.e. the percentage of either of these cancer cells in the GO/G1, S and G2/M phases of the cell cycle, when treated with IC 50 or IC 75 concentrations of bal6/7 for up to 72h. In the same manner, bal6/7 at IC 50 concentration induces neither early (annexin V-positive but PI-negative cells) nor late (annexin V-positive and PI-positive cells) apoptosis (Fig. 5Aa ) and U373 glioblastoma (Fig. 5Ab) (Fig. 5Ba and 5Bb ) unlike the positive control used, H 2 O 2 in MCF-7 breast cancer cells.
Bal6/7 effects on human A549 NSCLC and U373 glioblastoma cell morphology.
Determination of potential bal6/7 effects on cell cycle progression and apoptosis in human A549 NSCLC and U373 glioblastoma cells.
Reduction of bal6/7 cytotoxic effects by extraneous sugars or glycine.
[ATP] i depletion could be the consequence of treatment-induced sustained glycolysis and/or proteolysis. Accordingly, [ATP] i could be maintained by extraneous sugars and/or glycine. The addition of D-glucose (Fig. 6A) , L-fructose (Fig. 6B) or glycine (Fig. 6C) to A549 NSCLC and U373 GBM cell cultures 24 h prior to bal6/7 treatment, significantly (p<0.05 -<0.0001) reduced the cytotoxic effects of bal6/7, as revealed by the MTT colorimetric assay.
Bal6/7 markedly disorganizes the actin cytoskeleton.
The observed marked impairment in A549 and U373 cell proliferation and migration, as well as ATP depletion following bal6/7 treatment, suggested that the mixture's effects might be mediated, at least partly, by the disorganization of the actin cytoskeleton. As shown in Fig. 7 , bal6/7 indeed markedly and relatively rapidly over a 2-h period disorganized the actin cytoskeleton at its IC 75 concentrations in A549 NSCLC as well as in U373 glioblastoma cells.
In vivo anti-tumor effects of bal6/7. The in vivo anti-tumor effects of bal6/7 were investigated in a primary screening model, the L1210 murine leukemia model (16) at three different dose levels: 5, 2.5 and 1.25 mg/kg i.p. corresponding to half of the maximal tolerated dose [MTD in mice: 10 mg/kg (data not shown), MTD/4 and MTD/8]. Bal6/7 weakly but significantly (p=0.01-0.03) increased the survival of mice bearing L1210 leukemia (Fig. 8) at all three evaluated doses. However, there was no evidence of a dose-related response. The potential therapeutic benefit contributed by bal6/7 was evaluated by means of the T/C index. According to the guidelines of the National Cancer Institute, USA, when a compound is associated with a T/C index value equal or superior to 125%, it is considered to be active. In this study, bal6/7 displayed a T/C index of 130% (at all tested dose levels) indicating that the mixture increased by 30% the survival time of mice bearing L1210 leukemia. The in vivo anti-tumor effects observed here with bal6/7 are of the same magnitude as those observed with vincristine in this model (16) .
Discussion
Saponins to which balanitins belong are widely distributed in plants. Their surface-active properties are what distinguish these compounds from other glycosides. They readily dissolve in water to form colloidal solutions that foam upon shaking (20) . Saponins have a broad range of biological properties. Most are haemolytic and are toxic to cold-blooded animals, while certain saponins also display molluscicidal, anti-inflammatory, anti-fungal/anti-yeast, anti-bacterial/antimicrobial, anti-parasitic and anti-viral activity. Numerous reports have also highlighted the highly cytotoxic properties of many saponins (reviewed in ref. 20) . Saponins can act as potential anti-cancer agents by preventing carcinogenesis (21) (22) (23) or by exerting direct anti-proliferative and/or cytotoxic effects against cancer cells (24) (25) (26) (27) (28) even in vivo (26) .
In the current study, it has been demonstrated that a mixture of balanitin-6 and balanitin-7 (referred to as bal6/7) displays anti-cancer activity both in vitro and in vivo. A cellular imaging-based approach (11) (12) (13) 17) has also enabled demonstration that the anti-cancer activity of bal6/7 was not associated with membrane permeabilization or osmotic shock and thus did not appear to result from a detergent-like effect of the mixture (Fig. 3) . The anti-tumor activity of bal6/7 results from the fact that it markedly decreases [ATP] i (without a discernible increase in intra-cellular ROS), and this decrease in [ATP] i induces in turn a marked disorganization of the actin cytoskeleton (17) .
Distinct classes of natural products exert their cytotoxic activity through depletion of [ATP] i . This is the case for example for cardiac glycosides (9, 17) , isocarbostyril alkaloids such as pancratistatin (29) and tetrandrine, a bisbenzyl tetrahydroisoquinoline alkaloid (30) . Usually, a natural productinduced decrease in [ATP] i is accompanied by an increase in [ROS] i (29, 30) . This as indicated above is not the case for bal6/7 (Fig. 5 ). An [ROS] i increase is usually paralleled by activation of apoptosis (29, 30) which once more was not the case with respect to bal6/7 (Fig. 4) . In fact, the antitumor effects of bal6/7 seem to directly relate to a marked disorganization of the actin cytoskeleton (Fig. 7) through depletion of [ATP] i (Fig. 5) . The bal6/7-mediated anti-tumor effects which seem to occur via [ATP] i depletion, are indeed significantly reduced when D-glucose, L-fructose or glycine is added 24 h prior to bal6/7 to the culture media of human U373 glioblastoma and A549 NSCLC cells (Fig. 6) . Fructose (31) and glucose (32, 33) protection is mediated by preservation of cellular ATP supply by glycolysis. Glycine cytoprotection against cellular ATP depletion occurs via a decrease in total cellular proteolysis (34) . In other words, glycine could protect against cellular ATP depletion-induced cytotoxic effects by inhibiting proteolytic activities (34). The chemical hypoxia induced by bal6/7 in A549 NSCLC and U373 glioblastoma cells was not associated with mitochondrial membrane permeabilization (data not shown). In fact, measured ATP levels represent mainly the contribution of intact cells, as any ATP generated by functional mitochondria from highly permeable or completely disrupted cells would be rapidly hydrolyzed, much like exogenous ATP added to the incubation medium (35) . As already emphasized, intracellular ATP depletion causes marked actin cytoskeletal disruption, as also evidenced in the current study (Fig. 7) . In fact cellular ATP depletion in diverse cell types results in the net conversion of monomeric G-actin to polymeric Factin. This conversion itself results from altering the ratio of ATP-G-actin and ADP-G-actin, causing a net decrease in the concentration of thymosin-actin complexes as a consequence of the differential affinity of thymosin ß4 for ATP-and ADP-G-actin (36) . Increased detection of profiling-actin complexes during depletion indicates that profiling may participate in catalyzing nucleotide exchange during depletion (36) . Endothelial cell damage during simulated ischemia (reperfusion involves mitochondrial dysfunction, ATP depletion and ATP-dependent cytoskeletal disruption) is characterized by degradation of actin microfilaments, disappearance of focal adhesions and retraction of the cytoplasm (33) . In other cell types, including mouse embryo fibroblasts (37) , mouse leukemia cells (38) , microvilli of the apical membrane of proximal tubule cells (39) and human NSCLC cells (17) , ATP depletion also causes major perturbation of the actin cytoskeleton's organization. A functional actin cytoskeleton is vital for cell proliferation (during cytokinesis for example) and migration (40) . Thus, it seems likely that the anti-tumor effects associated with bal6/7 can be explained at least partly, by the bal6/7-induced depletion in [ATP] i which results in a major disorganization of the actin cytoskeleton.
The in vivo anti-tumor effects obtained with bal6/7, although modest, are nevertheless statistically significant. These preliminary in vivo data give some hope of developing more selective and potent balanitin derivatives for combating cancer. Balanitin-6 and -7, like dioscin and polyphyllin D, belong to a group of structurally similar diosgenyl saponins which can be synthesized by stepwise glycosylation (7). It should therefore be possible to generate novel hemi-synthetic derivatives of balanitin-6 and -7 with potentially improved in vitro and in vivo anti-cancer activity and reduced in vivo toxicity, and thus a markedly improved therapeutic ratio. This approach has already been successfully applied to certain types of cardenolides (9) and marine pyridoacridines [ascididemin and meridine (41) ] and quinolone derivatives (42) . Also, it has already been demonstrated that saponins from Tribulus terrestris L are less toxic to normal human fibroblasts than many cancer cell lines (28) , giving further hope of synthesizing balanitins with improved therapeutic ratios.
In playing a major role in mitosis, cell signaling and migration, microtubules and actin filaments are potentially interesting anti-cancer targets (43, 44) . However, while several anti-tubulin drugs (of natural origin) are already marketed for cancer (Paclitaxel ® , Taxotere ® , Navelbine ® , Oncovin ® , etc), no anti-actin compounds are yet marketed as anti-cancer drugs (13, 17) . The actin cytoskeleton represents a target against which a number of academic and pharmaceutical organizations are attempting to develop selective inhibitors to fight cancer (13, 17, (43) (44) (45) (46) (47) . Thus, novel derivatives of balanitins could have high therapeutic potential in cancer.
In conclusion, bal6/7-mediated in vitro non-apoptotic anti-cancer activities rely on depletion of [ATP] i leading to major disorganization of the actin cytoskeleton. The modest but nevertheless statistically significant in vivo activity of bal6/7 increases the possibility of developing more selective anti-cancer balanitin derivatives. 
